Nuts & Bolts of Biopharma Partnering
Looking for an in-licensing or out-licencing partner?
If you think you're ready to start engaging partners, watch this webinar to help you determine how close you are, and what work you still have to do.
A panel of six seasoned Biopharma partnering executives digs into the nuts and bolts of what to expect and how to ensure that due diligence goes smoothly.
Topics covered in the discussion include:
- The role, makeup and goals of an "early assessment" team
- The most critical factors for predicting an asset's potential
- Six aspects of a Total Product Profile typically evaluated before an asset even qualifies for consideration
- Which functions are represented by the members of a potential partners' core team and extended team
- When a terms sheet, before due diligence, makes sense
- Why you should only expose info that partners truly need to make decisions at each stage in their process
- How to stage the info disclosed to potential partners
- Best practices for the best long-term partnerships
MODERATOR AND PANELISTS:
Pullan Consulting
Partner, DL Snitman Inc and Former COO, Array BioPharma
David is a partner in a biotech business development-consulting agency, DL Snitman Inc. He is a Cofounder of Array BioPharma and lead over a dozen partnering deals, providing more then $600 M in non-dilutive capital.
Transaction and Due Diligence Senior Director for the Center of External Innovation at Takeda
Natalie is an accomplished biopharmaceutical Business Development professional with a strong track record of results oriented achievements in technology, company, and product licensing and acquisition. She has over 35 years of diversified biopharmaceutical experience, with scientific, financial, strategic, and business perspective.
Corporate and Business Development, Alliance Management, CorpDev Ventures
Jim has 30 years of life sciences professional experiences with projects and deals in over 30 countries with over 80 completed agreements across a range of transactions valued in excess of $900 million. His background includes a twenty-five year career with Bristol-Myers Squibb and Eli Lilly & Company and over fifteen years in international corporate business development and licensing roles.
Partner, McDonnell Boehnen Hulbert & Berghoff
Patrick's practice focuses on patent prosecution and technology licensing, with emphasis in biotechnology, pharmaceuticals, diagnostics, and medical devices. His 20-plus years of practice has emphasized patent portfolio management and the licensing, acquisition, and sale of intellectual property. Learn More
Director, Due Diligence Program Manager, Corporate Development, Shire
William currently serves as a Director, Due Diligence Program Manager within the Corporate Development department at Shire. He has 20 years of drug development, commercialization and strategic operations experience within the biopharmaceutical industry.
Chartered Organization Psychologist, Executive Consultant, Somerville Partners
With over 20 years of organizational development consulting with organizations, teams and individuals, Ann-Marie directly contributes to financial success by customizing solutions to help leaders increase employee engagement and contributions, align strategy and tactics, and elevate performance across the business. Learn More
SPONSORED BY:
